Market Access & Reimbursement
Integrated Market Access & Reimbursement
Reimbursement Challenges are Growing
Navigating market access and reimbursement requires more than traditional payer strategies; it demands a unified, data-driven approach.
EVERSANA’s Market Access & Reimbursement solutions simplify healthcare complexities by integrating predictive pricing analytics, Health Economics and Outcomes Research (HEOR), and targeted stakeholder engagement.
Whether you are launching a novel cell and gene therapy or optimizing gross-to-net for an established brand, our experts ensure optimal formulary coverage, minimize revenue leakage, and accelerate patient access across global markets.
Market Access Solutions and Services
A full spectrum of expertise across the market access ecosystem
Navigate Complex Payer Frameworks
Understanding the mindset of today’s healthcare gatekeepers requires more than high-level strategy—it demands deep, localized expertise. EVERSANA’s Market Access team engages directly with the critical decision makers shaping global reimbursement landscapes.
We tailor your product’s value proposition for Pharmacy Benefit Managers (PBMs), Health Plan Medical Directors, and Pharmacy & Therapeutics (P&T) Committees. By proactively aligning your clinical and Health Economics and Outcomes Research (HEOR) data with rigorous evaluation models, including ICER value frameworks, we ensure your assets withstands the highest levels of payer scrutiny, removing barriers to favorable formulary placement and patient access.
Market Access Resource Library and Thought Leadership
Explore our libraries to watch on-demand webinars and videos, and download white papers, case studies, and other recent articles.
Frequently Asked Questions
What is a comprehensive market access strategy in pharma?
A comprehensive market access strategy ensures that a therapy achieves optimal pricing, reimbursement, and formulary coverage. At EVERSANA, we build strategies that define clinical value, guide pricing governance, and leverage Health Economics and Outcomes Research (HEOR) to prove economic benefits to payers.
How does EVERSANA improve reimbursement outcomes for complex therapies?
We improve reimbursement outcomes by utilizing integrated data platforms, such as NAVLIN Price & Access Data, combined with expert payer engagement. Our approach minimizes gross-to-net leakage and accelerates benefit verification, which is particularly critical for high-cost Cell & Gene therapies and Oncology products.
Why is Real-World Evidence (RWE) critical for securing formulary coverage?
Payers increasingly demand proof of value beyond clinical trials. EVERSANA leverages robust Real-World Evidence (RWE) and patient analytics to demonstrate tangible clinical and economic benefits, closing evidence gaps and accelerating favorable formulary placement.
How do pharmaceutical companies navigate global pricing and market access?
Successfully navigating global pricing requires localized expertise and dynamic pricing software. EVERSANA provides comprehensive Global Market Access strategies, particularly across Europe and the Asia Pacific, ensuring compliance and accurate revenue management across diverse regulatory landscapes.